Table 2.
Summary of the pooled synergy rates
| Meropenem-based combinations | Tks
|
Checkerboard
|
Etest
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| Numberof studies | Number of isolates | Synergy rate | Number of studies | Number of isolates | Synergy rate | Number of studies | Number of isolates | Synergy rate | |
| Polymyxin B | 10 | 30 | 98.3% (95% CI, 83.7%–100.0%) | 4 | 99 | 37.0% (95% CI, 0.0%–100.0%) | 1 | 8 | 5/8 |
| Colistin | 12 | 132 | 60.4% (95% CI, 24.7%–91.8%) | 13 | 189 | 58.8% (95% CI, 29.4%–85.6%) | 4 | 122 | 39.2% (95% CI, 0.0%–97.7%) |
| Rifampicin | 4 | 20 | 89.4% (95% CI, 57.2%–100.0%) | 3 | 52 | 56.3% (95% CI, 8.7%–97.8%) | 1 | 40 | 1/40 |
| Tigecycline | 6 | 36 | 24.5% (95% CI, 1.0%–58.4%) | 2 | 35 | 7/35 | 2 | 100 | 23/100 |
| Sulbactam | 5 | 69 | 54.8% (95% CI, 39.7%–69.6%) | 8 | 405 | 25.2% (95% CI, 16.1%–36.2%) | 3 | 102 | 35.1% (95% CI, 21.4%–50.1%) |
| Cefoprazone/sulbactam | 0 | 0 | 0 | 6 | 309 | 7.4% (95% CI, 1.4%–16.6%) | 2 | 140 | 61/140 |
| Ciprofloxacin | 1 | 40 | 18/40 | 3 | 178 | 0.3% (95% CI, 0.0%–3.5%) | 0 | 0 | 0 |
| Amikacin | 2 | 9 | 8/9 | 2 | 128 | 67/128 | 0 | 0 | 0 |
Abbreviation: Tks, time-kill synergy.